The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Department of Radiation Oncology, Amsterdam, The Netherlands.
Radiother Oncol. 2011 Jan;98(1):51-6. doi: 10.1016/j.radonc.2010.10.024. Epub 2010 Dec 8.
To find parameters that predict which head and neck patients benefit from a sequentially delivered boost treatment plan compared to a simultaneously delivered plan, with the aim to spare the salivary glands.
We evaluated 50 recently treated head and neck cancer patients. Apart from the clinical plan with a sequentially (SEQ) given boost using an Intensity Modulated Radiotherapy Technique (IMRT), a simultaneous integrated boost (SIB) technique plan was constructed with the same beam set-up. The mean dose to the parotid glands was calculated and compared. The elective nodal areas were bilateral in all cases, with a boost on either one side or both sides of the neck.
When the parotid gland volume and the Planning Target Volume (PTV) for the boost overlap there is on average a lower dose to the parotid gland with a SIB technique (-1.2 Gy), which is, however, not significant (p=0.08). For all parotid glands with no boost PTV overlap, there is a benefit from a SEQ technique compared to a SIB technique for the gland evaluated (on average a 2.5 Gy lower dose to the parotid gland, p<0.001). When the distance between gland and PTV is 0-1 cm, this difference is on average 0.8 Gy, for 1-2 cm distance 2.9 Gy and for glands with a distance greater than 2 cm, 3.3 Gy. When the lymph nodes on the evaluated side are also included in the boost PTV, however, this relationship between the distance and the gain of a SEQ seems less clear.
A sequentially delivered boost technique results in a better treatment plan for most cases, compared to a simultaneous integrated boost IMRT technique, if the boost PTV is more than 1 cm away from at least one parotid gland.
寻找能够预测头颈部患者从序贯递增强化治疗计划中获益的参数,与同时递增强化计划相比,旨在保护唾液腺。
我们评估了 50 名最近接受治疗的头颈部癌症患者。除了使用强度调制放射治疗技术(IMRT)序贯(SEQ)给予的临床计划外,还构建了具有相同射束设置的同时整合强化(SIB)技术计划。计算并比较了腮腺的平均剂量。所有病例的选择性淋巴结区域均为双侧,颈部的一侧或双侧均有强化。
当腮腺体积和强化的计划靶区(PTV)重叠时,SIB 技术对腮腺的平均剂量较低(-1.2 Gy),但差异无统计学意义(p=0.08)。对于没有强化 PTV 重叠的所有腮腺,与 SIB 技术相比,SEQ 技术对所评估的腮腺有获益(腮腺平均剂量低 2.5 Gy,p<0.001)。当腺体与 PTV 之间的距离为 0-1 cm 时,这种差异平均为 0.8 Gy,距离为 1-2 cm 时为 2.9 Gy,距离大于 2 cm 时为 3.3 Gy。然而,如果评估侧的淋巴结也包含在强化 PTV 中,那么距离与 SEQ 增益之间的关系就不太明显了。
与同时递增强化 IMRT 技术相比,如果强化 PTV 距离至少一个腮腺超过 1 cm,则序贯递增强化技术可使大多数病例获得更好的治疗计划。